Does Adding Transdermal Nitroglycerine to Other Therapies Used for Management of Left-sided Congestive Heart Failure in Dogs Speed the Resolution of Clinical Signs?

A Knowledge Summary by

Jenefer R Stillion DVM, DACVECC
Søren R Boysen DVM, DACVECC

1 Western Veterinary Specialist and Emergency Centre, Calgary, Canada
2 Department of Veterinary Clinical and Diagnostic Sciences, Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada

* Corresponding Author (srboysen@ucalgary.ca)

There is an erratum to this paper published in Veterinary Evidence Vol 3, Issue 1 (2018): http://dx.doi.org/10.18849/ve.v3i1.168

ISSN: 2396-9776
Published: 12 Dec 2017
Updated: 01 Feb 2018
In: Vol 2, Issue 4
DOI: http://dx.doi.org/10.18849/ve.v2i4.115
Reviewed by: Myra Forster-van Hijfte (CertVR CertSAM DipECVIM-ca FRCVS) and William Chandler (BVetMed, MRCVS)

Next Review Date: 02 Jan 2019
Knowledge Summary

Clinical bottom line

There is very weak veterinary clinical and experimental evidence based upon a limited number of studies to indicate that adding transdermal nitroglycerine to other therapies used for management of left-sided congestive heart failure in dogs speeds the resolution of clinical signs.

Question

Does adding transdermal nitroglycerine to other therapies used for management of left-sided congestive heart failure in dogs speed the resolution of clinical signs?

Clinical Scenario

Transdermal nitroglycerin is frequently recommended as an adjunct therapy in many canine treatment protocols for left-sided congestive heart failure due to its preload and afterload reducing effects. Does adding transdermal nitroglycerin to other therapies used for management of left-sided congestive heart failure in dogs speed the resolution of clinical signs?

The Evidence

There is no evidence in the literature to suggest transdermal nitroglycerin speeds resolution of clinical signs in dogs with pulmonary oedema secondary to left-sided congestive heart failure. There is equivocal to weak evidence that transdermal nitroglycerin reduces systolic and/or mean arterial blood pressure in dogs. There is no evidence that transdermal nitroglycerin has any effect on resolution of any clinical signs of left-sided congestive heart failure. Although there are no reports of adverse harm associated with transdermal nitroglycerin, there are insufficient clinical studies to be able to state nitroglycerin does not have any adverse affects in dogs.

Summary of the evidence

Nakayama (2007)

| Population: | mixed breed dogs with Seller’s grades 2+ or 3+ mitral regurgitation |
| Sample size: | 9 dogs |
| Intervention details: | Mitral regurgitation was produced by surgical disruption of the mitral valves. Five months after production of mitral regurgitation, left atrial dimension and ventricular function were measured using echocardiography/Doppler and left ventricular micromanometry. Nine mixed breed dogs weighing 21-32 kg were administered butorphanol (0.05 mg/kg IM) prior to the start of each study. Enalaprilat, nitroglycerin, ouabain, milrinone or placebo (IV saline, There was a one-week washout period between arms of the study to ensure at least 10 half-lives between exposures. Recordings were obtained, along with an ECG, during baseline and 30 minutes after |
dogs received IV (in random sequence) 0.3 mg/kg enalaprilat, 20mg/kg ouabain, or 100mg/kg of milrinone; or 2 inches of 2% nitroglycerin paste applied to the skin of the inner thigh over an area of 16 cm². All dogs also were given an IV (saline) and a transdermal placebo (Vaseline). Dogs were studied 1 hour and 2 hours after application.

**Study design:** Randomised controlled clinical trial

**Outcome studied:** The effect of 4 different cardioactive drugs on left ventricular function in dogs with mitral regurgitation of 5 months duration. Parameters studied included intracardiac dimension, peak aortic flow, left atrial diastolic and systolic function.

**Main findings:** (relevant to PICO question):
- When compared to placebo (Vaseline), transdermal nitroglycerin failed to produce an effect on any of the parameters studied.

**Limitations:** Small sample size. Surgically induced mitral regurgitation may not accurately reflect clinical mitral endocardiosis. No animals had clinical signs of congestive heart failure.

---

**Kanda (1995)**

**Population:** Healthy Beagle dogs

**Sample size:** 5 dogs in each group

**Intervention details:** There were 3 groups; Nitroglycerin tape at 2.5 mg/kg (NT-l, 5 mg nitroglycerin per 5 x 10 cm²) with placebo capsule, nifedipine given orally (3mg/kg) with placebo tape, and a control group that received a placebo (blank) capsule orally and pacebo tape. Placebo and nitroglycerine tape were applied to a clipped area of skin on the chest of healthy beagle dogs.

**Study design:** Prospective study (non-randomised, non-blinded)

**Outcome studied:** The effect of nitroglycerin tape compared to placebo tape on blood pressure (systolic and diastolic), heart rate and coronary blood flow in healthy beagle dogs. Baseline values recorded for 1 hour before drug administration and then at 30 min, 1 hour and every hour until 9 hours. Parameters were measured again 1 hours following removal of tape.

**Main findings:** (relevant to PICO question):
- Systolic blood pressure was decreased by 10-15%, compared to baseline, with application of nitroglycerin tape in awake healthy instrumented beagle dogs. The decrease was noted 1 hour after application, persisted for the duration of the study and returned to baseline values within 1 hour of removing the tape.
- Calculated (not directly measured) mean arterial pressure decreased 4-5 %.
- Diastolic blood pressure and heart rate were not affected.
Changes were noted 30 minutes after the application of nitroglycerin tape and remained constant for 8h.
No changes from baseline parameters were noted in the control group.

**Limitations:**
Small sample size may have failed to detect true differences that existed between groups or within groups. Decrease in blood pressure provides indirect evidence of the efficacy of nitroglycerin which does not equate to clinical improvement. Dogs were healthy and did not have any clinical signs of congestive heart failure.

<table>
<thead>
<tr>
<th>McKie (2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population:</strong></td>
</tr>
<tr>
<td><strong>Sample size:</strong></td>
</tr>
<tr>
<td><strong>Intervention details:</strong></td>
</tr>
<tr>
<td><strong>Study design:</strong></td>
</tr>
<tr>
<td><strong>Outcome studied:</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong></td>
</tr>
<tr>
<td><strong>Limitations:</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameswaran (1999)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population:</strong></td>
</tr>
<tr>
<td><strong>Sample size:</strong></td>
</tr>
<tr>
<td><strong>Intervention details:</strong></td>
</tr>
</tbody>
</table>
2.5cm strip of transdermal 2% nitroglycerin ointment was applied to the inner surface of the pinna in 10 dogs and 5 additional dogs (control group) were given only petrolatum.

<table>
<thead>
<tr>
<th>Study design:</th>
<th>Non-randomised clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome studied:</td>
<td>Splenic dilatation in healthy dogs anaesthetised with alpha chloralose after transdermal application of nitroglycerin. Splenic dimension and venous pressure were measured for 10 minutes before application and time from application of transdermal nitroglycerin to the initial change in dimension and to the maximal change in dimension (measured to the nearest second).</td>
</tr>
</tbody>
</table>

| Main findings: (relevant to PICO question): | • Splenic dimension increased significantly from baseline in all 10 dogs receiving transdermal nitroglycerin.  
• Splenic enlargement was noted within 482 ± 652 seconds after application of transdermal nitroglycerin with maximal dilatation at 861 ± 632 seconds.  
• Splenic venous pressure did not change significantly in dogs receiving transdermal nitroglycerin or in control dogs. |

| Limitations: | Animals were healthy and anaesthetised with alpha chloralose, whose physiologic effects are not well characterized in the literature for any species. Results of the present study may not translate to un-anaesthetised dogs with left-sided congestive heart failure. |

**Appraisal, application and reflection**

Given studies are lacking with regards to the efficacy of transdermal nitroglycerin when included as an adjunct treatment to other therapies in dogs with left-sided congestive heart failure, it’s use cannot be recommended in the management of these cases at this time. Future clinical studies are needed to evaluate the safety, efficacy and ideal dosage of transdermal nitroglycerin in the treatment of dogs with left-sided congestive heart failure.

**Methodology Section**

**Search Strategy**

<table>
<thead>
<tr>
<th>Databases searched and dates covered:</th>
<th>Pubmed Platform 1973- Week 1 2017], CAB Abstracts &lt;1973 to 2016 Week 51&gt;</th>
</tr>
</thead>
</table>
| Search terms:                        | Pubmed  
1 Search (((glyceryl trinitrat*) OR glyceryltrinitrat*) OR trinitrat glycerin*) OR nitro glycerin*) OR nitroglycerin* 16518  
2 Search ((((((heart) OR cardiac) OR CHF) OR cardio*) OR left ventricular) OR left ventricle*) OR LV) OR heart diseases) OR cardiovascular diseases 2866548  
3 Search (((((dog) OR dogs) OR canine) OR bitch*) OR canis) OR bitches 351249  
4 Search ((transdermal) OR cutaneous) OR ointment |
### Exclusion / Inclusion Criteria

**Exclusion:**
Study design did not involve dogs and/or was not relevant to the research questions asked.

**Inclusion:**
Any relevant primary veterinary research or systematic review which compared transdermal nitroglycerine to other therapies to answer the following question; “Does adding transdermal nitroglycerine to other therapies used for management of left-sided congestive heart failure in dogs speed the resolution of clinical signs?”

### Search Outcome

<table>
<thead>
<tr>
<th>Database</th>
<th>Number of results</th>
<th>Excluded – Did not address the PICO</th>
<th>Excluded – Proceedings and review articles with no evidence</th>
<th>Excluded – Given IV, did not compare groups, and did not address clinical question</th>
<th>Excluded – Single case report with no evidence to the question</th>
<th>Duplicate results</th>
<th>Total relevant papers</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed</td>
<td>10</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>CAB Abstracts</td>
<td>16</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

Total relevant papers when duplicates removed: 4
CONFLICT OF INTEREST

The author declares no conflict of interest.

REFERENCES


Intellectual Property Rights

Authors of Knowledge Summaries submitted to RCVS Knowledge for publication will retain copyright in their work, and will be required to grant to RCVS Knowledge a non-exclusive license of the rights of copyright in the materials including but not limited to the right to publish, re-publish, transmit, sell, distribute and otherwise use the materials in all languages and all media throughout the world, and to license or permit others to do so.

Disclaimer

Knowledge Summaries are a peer-reviewed article type which aims to answer a clinical question based on the best available current evidence. It does not override the responsibility of the practitioner. Informed decisions should be made by considering such factors as individual clinical expertise and judgement along with patient’s circumstances and owners’ values. Knowledge Summaries are a resource to help inform and any opinions expressed within the Knowledge Summaries are the author’s own and do not necessarily reflect the view of the RCVS Knowledge.

Veterinary Evidence and EBVM Network are RCVS Knowledge initiatives. For more information please contact us at editor@veterinaryevidence.org

RCVS Knowledge is the independent charity associated with the Royal College of Veterinary Surgeons (RCVS). Our ambition is to become a global intermediary for evidence based veterinary knowledge by providing access to information that is of immediate value to practicing veterinary professionals and directly contributes to evidence based clinical decision-making.

www.veterinaryevidence.org

RCVS Knowledge is a registered Charity No. 230886. Registered as a Company limited by guarantee in England and Wales No. 598443.

Registered Office:
Belgravia House
62-64 Horseferry Road
London SW1P 2AF

This work is licensed under a Creative Commons Attribution 4.0 International License.